With a high complexity CLIA-certified, CAP-accredited clinical laboratory, Sapient upholds stringent standards for testing accuracy and reproducible results.
Our projects typically begin in our R&D lab with nontargeted discovery screenings using Sapient’s high throughput rLC-MS systems, which broadly capture thousands of dynamic biomarkers per sample.
Potential for discovery is highly dependent on these systems delivering reproducible measures with limited technical variance, and we perform rigorous quality control with monitoring of over 500 parameters related to rLC-MS function, data quality, and sample integrity.
We understand that biomarker data quality is of the utmost importance for confident decision making, particularly when working with complex and dynamic measures.
Sapient has passed an in-depth inspection by the College of American Pathologists (CAP) of our clinical laboratory facilities, equipment, processes, and quality control measures.
Once we have identified and validated a key biomarker of interest, we can use our clinical lab to translate it into a targeted assay for use in a clinical setting, including for clinical trials. Sapient’s clinical lab is certified as a high complexity CLIA lab, developing and performing advanced biomarker assays that adhere to the most stringent CLIA regulations.
Our clinical lab also holds CAP accreditation, confirming we uphold or exceed CLIA standards with exceptional testing proficiency, accuracy, and reliability.
We’ll help you rapidly identify and develop biomarkers for regulated clinical applications.
"*" indicates required fields
